中文

Our History

Overview

How it All Began

The company was founded in 1998 by our Chairman and Executive Director Dr. Zhaohua Chang. However the MicroPort® story and the motivation for our unique development begins in 1995, when the Shanghai Municipal Government invited a group of leading globally accomplished Chinese scholar's based internationally to form a delegation to visit Shanghai. Back then Dr. Chang was a highly successful and respected leading research scientist working in some of the best scientific institutions, companies and Universities in the USA.

Returning to China as a visiting delegate provided the initial spark of inspiration. Dr. Chang witnessed, after years living abroad, the remarkable and rapid changes facing his homeland. Knowing that China's device sector was completely dependent on expensive imported technology and was extremely disadvantaged in terms of it's capabilities for independent research and development, Dr. Chang determined to do something concrete to change the future.

So during this brief visit to Shanghai in 1995 the history of MicroPort® began when Dr. Chang decided it was time to return home and bring his scientific expertise back to China for the benefit of the Chinese people. Three years later Dr. Chang had set about developing a uniquely Chinese business to provide a home in China for likeminded scientists, and MicroPort® was born.

An academic scholar and scientist with a passion for bioengineering and some good ideas, made a significant contribution to the establishment of high-tech medical device development and manufacturer in China. This is where our company history begins.

Those early years were tough and the company faced many difficulties. At times it seemed an impossible dream and it appeared events conspired to frustrate and undermine the company just as it was beginning to establish a foundation.

Fortunately, our founder was steadfast in his own confidence and determination to create a different kind of company. It was his perseverance to gather together what he often refers to as the 'dream team' of leadership and scientists that enabled the realisation of his original vision.

Milestones
2017
  • MPSC was listed in the Shenzhen-Hong Kong Stock Connect

  • "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" Project Won the Second Prize of State Science and Technology Progress Award

2016
  • "Key technology and industrialization platform for minimally invasive interventional and implantable medical devices" project won prestigious class II prize of State Science and Technology Advancement Award

  • MicroPort® EP Columbus® 3D EP Navigation System received the CFDA registration certificate

  • MicroPort® Online network service platform "Life Line Live" was officially launched

  • MicroPort® was awarded Five Star Credit Enterprise

2015
  • Firehawk™ Rapamycin Target Eluting Coronary Stent received CE Mark certificate

  • WILLIS™ clinical application project won prestigious class II prize of State Science and Technology Advancement Award

  • EVOLUTION™ medial-pivot knee system received CFDA approval

  • MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line

  • Shanghai MicroPort Orthopedics Co., Ltd. moved to new headquarters in Suzhou

  • MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone

  • MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established

  • Liangzhi Creative Center and Knowledge & Action Center at corporate HQ were officially put into use

  • Shanghai MicroPort EP MedTech Co., Ltd. successfully completed restructuring

  • Shanghai MicroPort EP MedTech Co., Ltd. received "Shanghai Hi-Tech Enterprise" honor

2014
  • Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business

  • Completed acquisition of Wright Medical's OrthoRecon business

  • Acquired drug eluting stent related assets and intellectual properties from Cordis

  • Firehawk™ rapamycin target eluting coronary stent system received CFDA approval

  • Corporate headquarters relocated to 1601 Zhangdong Rd at completed industrialization base in Zhangjiang Riverfront harbor

  • Established MPSC Research & Engineering Academy

2013
  • WILLIS™ intracranial stent graft system received SFDA approval

  • Construction began on Suzhou orthopedic industrial base

  • Acquired Wright Medical's OrthoRecon Business for $290 Million

  • Shanghai MicroPort EP MedTech Co., Ltd.'s FireMagic™, EasyFinder™, EasyLoop™ and FireMagic™ 3D and Columbus™ received CE mark certificates

2012
  • Initiated "United Fleets of MicroPort®" operating model

  • Shanghai D-Pulse Medical Co., Ltd. was established in Shanghai International Medical Zone

  • Shanghai MicroPort NeuroTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established in Shanghai International Medical Zone

  • Total tax contribution reached 1 billion RMB

  • Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd.

  • MicroPort Orthopedics (Suzhou) Co., Ltd. was established in Suzhou Industrial Park

  • MicroPort Medical (Shanghai) Co., Ltd. was renamed Shanghai MicroPort Medical (Group) Co., Ltd.

  • MicroPort International Corp. Ltd. was established in Hong Kong

2011
  • Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd.

  • Coronary drug eluting stent implants reached over 700,000 units

  • Undertook national R&D projects accumulating to more than 100 million RMB

  • MicroPort Medical (Jiaxing) Co., Ltd. was established in Jiaxing Science City

2010
  • Shanghai MicroPort EP MedTech Co., Ltd. was established in Shanghai International Medical Zone

  • MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK)

  • Annual sales exceeded 100 million USD

2009
  • Shanghai MicroPort Orthopedics Co., Ltd. was established in Shanghai International Medical Zone

  • FireMagic™ ablation catheter received SFDA approval

  • Construction of a new industrialization base began in Zhangjiang Riverfront Harbor

  • Received 54.3 million RMB from Shanghai municipal government to develop and enhance industrial capacity in minimally invasive medicine

2008
  • Shanghai MicroPort Lifesciences Co, Ltd. was established at the Shanghai International Medical Zone

  • Officially entered diabetes business with acquisition of Beijing PanGeRui Medical Device Company

  • Firebird2™ coronary drug eluting stent system received SFDA approval

  • Began experimental implementation of "Vertical Integration & Horizontal Connection" management concept

2007
  • Firebird™ coronary drug eluting stent system won prestigious class II prize of State Science and Technology Advancement Award

2006
  • Coronary drug eluting stent implants reached over 100,000 units

  • MicroPort Scientific Corporation was established

  • Entered Latin American market with successful auditing by ANMAT of Argentina

2005
  • Firebird™ drug eluting stent system was named Shanghai's key new product

  • Annual sales exceeded 100 million RMB

2004
  • Firebird™ drug eluting stent system received SFDA approval

  • Mustang™ coronary stent system received CE mark certificate

2003
  • Officially entered international market with PTCA Balloon dilatation catheters by receiving import license from Ministry of Health, Labor and Welfare of Japan

2002
  • Received major funding from National Development and Reform Commission

2001
  • Moved into new headquarters at 501 Newton Road, Zhangjiang Hi-Tech Park

  • Received "Shanghai Hi-Tech Enterprise" honor and business became profitable

2000
  • Mustang™ bare metal stent received SFDA approval

1999
  • PTCA balloon dilatation catheter received SFDA approval, very first sale made

1998
  • Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai